PLATELET-ACTIVATING FACTOR (PAF) IN EXPERIMENTAL AND CLINICAL SEPSIS
| Autor: | Philip Ovadia, Guenther Mathiak, Damian Szewczyk, Fizan Abdullah, Reuven Rabinovici |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Platelet-activating factor
business.industry Critical Care and Intensive Care Medicine medicine.disease Bioinformatics Clinical trial Sepsis chemistry.chemical_compound Mediator chemistry Clinical evidence Emergency Medicine medicine Animals Humans Disease process Platelet Activating Factor Gram-Negative Bacterial Infections business |
| Zdroj: | Shock. 7:391-404 |
| ISSN: | 1073-2322 |
| DOI: | 10.1097/00024382-199706000-00001 |
| Popis: | Despite considerable progress in understanding the pathogenic mechanisms of Gram-negative sepsis, the outcome of septic patients has not significantly improved. There are ample data that support a role for inflammatory mediators in sepsis that act in synergy with infectious agents to initiate and propagate the disease process. One such mediator is the glycerophospholipid platelet-activating factor (PAF). The objective of the present review is to summarize experimental and clinical evidence implicating PAF as a mediator in the pathomechanism of sepsis. This review is timely because many potent and selective PAF antagonists have matured for clinical development and a careful analysis of the data that support or refute the merit of clinical trials with such compounds may be important for both academic and pharmaceutical applications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|